ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Focal Segmental Glomerulosclerosis Drug Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-31I9260
Home | Market Reports | Health| Pharmacy
Global Focal Segmental Glomerulosclerosis Drug Market Insights and Forecast to 2028
BUY CHAPTERS

Global Focal Segmental Glomerulosclerosis Drug Market Research Report 2025

Code: QYRE-Auto-31I9260
Report
September 2025
Pages:85
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Complexa Inc
Dimerix Bioscience Pty Ltd
GlaxoSmithKline PLC
Retrophin
Takeda
Variant Pharmaceuticals Inc

Focal Segmental Glomerulosclerosis Drug Market Size

The global market for Focal Segmental Glomerulosclerosis Drug was valued at US$ 10830 million in the year 2024 and is projected to reach a revised size of US$ 15960 million by 2031, growing at a CAGR of 5.8% during the forecast period.

Focal Segmental Glomerulosclerosis Drug Market

Focal Segmental Glomerulosclerosis Drug Market

North American market for Focal Segmental Glomerulosclerosis Drug is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Focal Segmental Glomerulosclerosis Drug is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Focal Segmental Glomerulosclerosis Drug include Complexa Inc, Dimerix Bioscience Pty Ltd, GlaxoSmithKline Plc, Retrophin Inc, Takeda, Variant Pharmaceuticals Inc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Focal Segmental Glomerulosclerosis Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Focal Segmental Glomerulosclerosis Drug.
The Focal Segmental Glomerulosclerosis Drug market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Focal Segmental Glomerulosclerosis Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Focal Segmental Glomerulosclerosis Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Focal Segmental Glomerulosclerosis Drug Market Report

Report Metric Details
Report Name Focal Segmental Glomerulosclerosis Drug Market
Accounted market size in year US$ 10830 million
Forecasted market size in 2031 US$ 15960 million
CAGR 5.8%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Losmapimod
  • SHP-627
  • Sparsentan
  • TM-5484
  • Others
Segment by Application
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Complexa Inc, Dimerix Bioscience Pty Ltd, GlaxoSmithKline Plc, Retrophin Inc, Takeda, Variant Pharmaceuticals Inc
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Focal Segmental Glomerulosclerosis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Focal Segmental Glomerulosclerosis Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Focal Segmental Glomerulosclerosis Drug Market growing?

Ans: The Focal Segmental Glomerulosclerosis Drug Market witnessing a CAGR of 5.8% during the forecast period 2025-2031.

What is the Focal Segmental Glomerulosclerosis Drug Market size in 2031?

Ans: The Focal Segmental Glomerulosclerosis Drug Market size in 2031 will be US$ 15960 million.

Who are the main players in the Focal Segmental Glomerulosclerosis Drug Market report?

Ans: The main players in the Focal Segmental Glomerulosclerosis Drug Market are Complexa Inc, Dimerix Bioscience Pty Ltd, GlaxoSmithKline Plc, Retrophin Inc, Takeda, Variant Pharmaceuticals Inc

What are the Application segmentation covered in the Focal Segmental Glomerulosclerosis Drug Market report?

Ans: The Applications covered in the Focal Segmental Glomerulosclerosis Drug Market report are Clinic, Research Center, Hospital, Others

What are the Type segmentation covered in the Focal Segmental Glomerulosclerosis Drug Market report?

Ans: The Types covered in the Focal Segmental Glomerulosclerosis Drug Market report are Losmapimod, SHP-627, Sparsentan, TM-5484, Others

Recommended Reports

Kidney Disease Drugs

Renal Therapy Devices

Rare Disease Treatments

1 Focal Segmental Glomerulosclerosis Drug Market Overview
1.1 Product Definition
1.2 Focal Segmental Glomerulosclerosis Drug by Type
1.2.1 Global Focal Segmental Glomerulosclerosis Drug Market Value Comparison by Type (2024 VS 2031)
1.2.2 Losmapimod
1.2.3 SHP-627
1.2.4 Sparsentan
1.2.5 TM-5484
1.2.6 Others
1.3 Focal Segmental Glomerulosclerosis Drug by Application
1.3.1 Global Focal Segmental Glomerulosclerosis Drug Market Value by Application (2024 VS 2031)
1.3.2 Clinic
1.3.3 Research Center
1.3.4 Hospital
1.3.5 Others
1.4 Global Focal Segmental Glomerulosclerosis Drug Market Size Estimates and Forecasts
1.4.1 Global Focal Segmental Glomerulosclerosis Drug Revenue 2020-2031
1.4.2 Global Focal Segmental Glomerulosclerosis Drug Sales 2020-2031
1.4.3 Global Focal Segmental Glomerulosclerosis Drug Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Focal Segmental Glomerulosclerosis Drug Market Competition by Manufacturers
2.1 Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Manufacturers (2020-2025)
2.2 Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Focal Segmental Glomerulosclerosis Drug Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Focal Segmental Glomerulosclerosis Drug, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Focal Segmental Glomerulosclerosis Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Focal Segmental Glomerulosclerosis Drug, Product Type & Application
2.7 Global Key Manufacturers of Focal Segmental Glomerulosclerosis Drug, Date of Enter into This Industry
2.8 Global Focal Segmental Glomerulosclerosis Drug Market Competitive Situation and Trends
2.8.1 Global Focal Segmental Glomerulosclerosis Drug Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Focal Segmental Glomerulosclerosis Drug Players Market Share by Revenue
2.8.3 Global Focal Segmental Glomerulosclerosis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Focal Segmental Glomerulosclerosis Drug Market Scenario by Region
3.1 Global Focal Segmental Glomerulosclerosis Drug Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Focal Segmental Glomerulosclerosis Drug Sales by Region: 2020-2031
3.2.1 Global Focal Segmental Glomerulosclerosis Drug Sales by Region: 2020-2025
3.2.2 Global Focal Segmental Glomerulosclerosis Drug Sales by Region: 2026-2031
3.3 Global Focal Segmental Glomerulosclerosis Drug Revenue by Region: 2020-2031
3.3.1 Global Focal Segmental Glomerulosclerosis Drug Revenue by Region: 2020-2025
3.3.2 Global Focal Segmental Glomerulosclerosis Drug Revenue by Region: 2026-2031
3.4 North America Focal Segmental Glomerulosclerosis Drug Market Facts & Figures by Country
3.4.1 North America Focal Segmental Glomerulosclerosis Drug Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Focal Segmental Glomerulosclerosis Drug Sales by Country (2020-2031)
3.4.3 North America Focal Segmental Glomerulosclerosis Drug Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Focal Segmental Glomerulosclerosis Drug Market Facts & Figures by Country
3.5.1 Europe Focal Segmental Glomerulosclerosis Drug Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Focal Segmental Glomerulosclerosis Drug Sales by Country (2020-2031)
3.5.3 Europe Focal Segmental Glomerulosclerosis Drug Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Focal Segmental Glomerulosclerosis Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Focal Segmental Glomerulosclerosis Drug Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Focal Segmental Glomerulosclerosis Drug Sales by Region (2020-2031)
3.6.3 Asia Pacific Focal Segmental Glomerulosclerosis Drug Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Focal Segmental Glomerulosclerosis Drug Market Facts & Figures by Country
3.7.1 Latin America Focal Segmental Glomerulosclerosis Drug Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Focal Segmental Glomerulosclerosis Drug Sales by Country (2020-2031)
3.7.3 Latin America Focal Segmental Glomerulosclerosis Drug Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Focal Segmental Glomerulosclerosis Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Focal Segmental Glomerulosclerosis Drug Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales by Country (2020-2031)
3.8.3 Middle East and Africa Focal Segmental Glomerulosclerosis Drug Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Focal Segmental Glomerulosclerosis Drug Sales by Type (2020-2031)
4.1.1 Global Focal Segmental Glomerulosclerosis Drug Sales by Type (2020-2025)
4.1.2 Global Focal Segmental Glomerulosclerosis Drug Sales by Type (2026-2031)
4.1.3 Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Type (2020-2031)
4.2 Global Focal Segmental Glomerulosclerosis Drug Revenue by Type (2020-2031)
4.2.1 Global Focal Segmental Glomerulosclerosis Drug Revenue by Type (2020-2025)
4.2.2 Global Focal Segmental Glomerulosclerosis Drug Revenue by Type (2026-2031)
4.2.3 Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Type (2020-2031)
4.3 Global Focal Segmental Glomerulosclerosis Drug Price by Type (2020-2031)
5 Segment by Application
5.1 Global Focal Segmental Glomerulosclerosis Drug Sales by Application (2020-2031)
5.1.1 Global Focal Segmental Glomerulosclerosis Drug Sales by Application (2020-2025)
5.1.2 Global Focal Segmental Glomerulosclerosis Drug Sales by Application (2026-2031)
5.1.3 Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Application (2020-2031)
5.2 Global Focal Segmental Glomerulosclerosis Drug Revenue by Application (2020-2031)
5.2.1 Global Focal Segmental Glomerulosclerosis Drug Revenue by Application (2020-2025)
5.2.2 Global Focal Segmental Glomerulosclerosis Drug Revenue by Application (2026-2031)
5.2.3 Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Application (2020-2031)
5.3 Global Focal Segmental Glomerulosclerosis Drug Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Complexa Inc
6.1.1 Complexa Inc Company Information
6.1.2 Complexa Inc Description and Business Overview
6.1.3 Complexa Inc Focal Segmental Glomerulosclerosis Drug Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Complexa Inc Focal Segmental Glomerulosclerosis Drug Product Portfolio
6.1.5 Complexa Inc Recent Developments/Updates
6.2 Dimerix Bioscience Pty Ltd
6.2.1 Dimerix Bioscience Pty Ltd Company Information
6.2.2 Dimerix Bioscience Pty Ltd Description and Business Overview
6.2.3 Dimerix Bioscience Pty Ltd Focal Segmental Glomerulosclerosis Drug Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Dimerix Bioscience Pty Ltd Focal Segmental Glomerulosclerosis Drug Product Portfolio
6.2.5 Dimerix Bioscience Pty Ltd Recent Developments/Updates
6.3 GlaxoSmithKline Plc
6.3.1 GlaxoSmithKline Plc Company Information
6.3.2 GlaxoSmithKline Plc Description and Business Overview
6.3.3 GlaxoSmithKline Plc Focal Segmental Glomerulosclerosis Drug Sales, Revenue and Gross Margin (2020-2025)
6.3.4 GlaxoSmithKline Plc Focal Segmental Glomerulosclerosis Drug Product Portfolio
6.3.5 GlaxoSmithKline Plc Recent Developments/Updates
6.4 Retrophin Inc
6.4.1 Retrophin Inc Company Information
6.4.2 Retrophin Inc Description and Business Overview
6.4.3 Retrophin Inc Focal Segmental Glomerulosclerosis Drug Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Retrophin Inc Focal Segmental Glomerulosclerosis Drug Product Portfolio
6.4.5 Retrophin Inc Recent Developments/Updates
6.5 Takeda
6.5.1 Takeda Company Information
6.5.2 Takeda Description and Business Overview
6.5.3 Takeda Focal Segmental Glomerulosclerosis Drug Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Takeda Focal Segmental Glomerulosclerosis Drug Product Portfolio
6.5.5 Takeda Recent Developments/Updates
6.6 Variant Pharmaceuticals Inc
6.6.1 Variant Pharmaceuticals Inc Company Information
6.6.2 Variant Pharmaceuticals Inc Description and Business Overview
6.6.3 Variant Pharmaceuticals Inc Focal Segmental Glomerulosclerosis Drug Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Variant Pharmaceuticals Inc Focal Segmental Glomerulosclerosis Drug Product Portfolio
6.6.5 Variant Pharmaceuticals Inc Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Focal Segmental Glomerulosclerosis Drug Industry Chain Analysis
7.2 Focal Segmental Glomerulosclerosis Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Focal Segmental Glomerulosclerosis Drug Production Mode & Process Analysis
7.4 Focal Segmental Glomerulosclerosis Drug Sales and Marketing
7.4.1 Focal Segmental Glomerulosclerosis Drug Sales Channels
7.4.2 Focal Segmental Glomerulosclerosis Drug Distributors
7.5 Focal Segmental Glomerulosclerosis Drug Customer Analysis
8 Focal Segmental Glomerulosclerosis Drug Market Dynamics
8.1 Focal Segmental Glomerulosclerosis Drug Industry Trends
8.2 Focal Segmental Glomerulosclerosis Drug Market Drivers
8.3 Focal Segmental Glomerulosclerosis Drug Market Challenges
8.4 Focal Segmental Glomerulosclerosis Drug Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Complexa Inc
Dimerix Bioscience Pty Ltd
GlaxoSmithKline PLC
Retrophin
Takeda
Variant Pharmaceuticals Inc
List of Tables
 Table 1. Global Focal Segmental Glomerulosclerosis Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Focal Segmental Glomerulosclerosis Drug Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Focal Segmental Glomerulosclerosis Drug Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Focal Segmental Glomerulosclerosis Drug Sales (K Pcs) of Key Manufacturers (2020-2025)
 Table 5. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Focal Segmental Glomerulosclerosis Drug Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Focal Segmental Glomerulosclerosis Drug Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Focal Segmental Glomerulosclerosis Drug Average Price (USD/Pcs) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Focal Segmental Glomerulosclerosis Drug, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Focal Segmental Glomerulosclerosis Drug, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Focal Segmental Glomerulosclerosis Drug, Product Type & Application
 Table 12. Global Key Manufacturers of Focal Segmental Glomerulosclerosis Drug, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Focal Segmental Glomerulosclerosis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Focal Segmental Glomerulosclerosis Drug as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Focal Segmental Glomerulosclerosis Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Focal Segmental Glomerulosclerosis Drug Sales by Region (2020-2025) & (K Pcs)
 Table 18. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Region (2020-2025)
 Table 19. Global Focal Segmental Glomerulosclerosis Drug Sales by Region (2026-2031) & (K Pcs)
 Table 20. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Region (2026-2031)
 Table 21. Global Focal Segmental Glomerulosclerosis Drug Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Region (2020-2025)
 Table 23. Global Focal Segmental Glomerulosclerosis Drug Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Region (2026-2031)
 Table 25. North America Focal Segmental Glomerulosclerosis Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Focal Segmental Glomerulosclerosis Drug Sales by Country (2020-2025) & (K Pcs)
 Table 27. North America Focal Segmental Glomerulosclerosis Drug Sales by Country (2026-2031) & (K Pcs)
 Table 28. North America Focal Segmental Glomerulosclerosis Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Focal Segmental Glomerulosclerosis Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Focal Segmental Glomerulosclerosis Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Focal Segmental Glomerulosclerosis Drug Sales by Country (2020-2025) & (K Pcs)
 Table 32. Europe Focal Segmental Glomerulosclerosis Drug Sales by Country (2026-2031) & (K Pcs)
 Table 33. Europe Focal Segmental Glomerulosclerosis Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Focal Segmental Glomerulosclerosis Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Focal Segmental Glomerulosclerosis Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Focal Segmental Glomerulosclerosis Drug Sales by Region (2020-2025) & (K Pcs)
 Table 37. Asia Pacific Focal Segmental Glomerulosclerosis Drug Sales by Region (2026-2031) & (K Pcs)
 Table 38. Asia Pacific Focal Segmental Glomerulosclerosis Drug Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Focal Segmental Glomerulosclerosis Drug Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Focal Segmental Glomerulosclerosis Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Focal Segmental Glomerulosclerosis Drug Sales by Country (2020-2025) & (K Pcs)
 Table 42. Latin America Focal Segmental Glomerulosclerosis Drug Sales by Country (2026-2031) & (K Pcs)
 Table 43. Latin America Focal Segmental Glomerulosclerosis Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Focal Segmental Glomerulosclerosis Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales by Country (2020-2025) & (K Pcs)
 Table 47. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales by Country (2026-2031) & (K Pcs)
 Table 48. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Focal Segmental Glomerulosclerosis Drug Sales (K Pcs) by Type (2020-2025)
 Table 51. Global Focal Segmental Glomerulosclerosis Drug Sales (K Pcs) by Type (2026-2031)
 Table 52. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Type (2020-2025)
 Table 53. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Type (2026-2031)
 Table 54. Global Focal Segmental Glomerulosclerosis Drug Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Focal Segmental Glomerulosclerosis Drug Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Type (2020-2025)
 Table 57. Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Type (2026-2031)
 Table 58. Global Focal Segmental Glomerulosclerosis Drug Price (USD/Pcs) by Type (2020-2025)
 Table 59. Global Focal Segmental Glomerulosclerosis Drug Price (USD/Pcs) by Type (2026-2031)
 Table 60. Global Focal Segmental Glomerulosclerosis Drug Sales (K Pcs) by Application (2020-2025)
 Table 61. Global Focal Segmental Glomerulosclerosis Drug Sales (K Pcs) by Application (2026-2031)
 Table 62. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Application (2020-2025)
 Table 63. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Application (2026-2031)
 Table 64. Global Focal Segmental Glomerulosclerosis Drug Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Focal Segmental Glomerulosclerosis Drug Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Application (2020-2025)
 Table 67. Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Application (2026-2031)
 Table 68. Global Focal Segmental Glomerulosclerosis Drug Price (USD/Pcs) by Application (2020-2025)
 Table 69. Global Focal Segmental Glomerulosclerosis Drug Price (USD/Pcs) by Application (2026-2031)
 Table 70. Complexa Inc Company Information
 Table 71. Complexa Inc Description and Business Overview
 Table 72. Complexa Inc Focal Segmental Glomerulosclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 73. Complexa Inc Focal Segmental Glomerulosclerosis Drug Product
 Table 74. Complexa Inc Recent Developments/Updates
 Table 75. Dimerix Bioscience Pty Ltd Company Information
 Table 76. Dimerix Bioscience Pty Ltd Description and Business Overview
 Table 77. Dimerix Bioscience Pty Ltd Focal Segmental Glomerulosclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 78. Dimerix Bioscience Pty Ltd Focal Segmental Glomerulosclerosis Drug Product
 Table 79. Dimerix Bioscience Pty Ltd Recent Developments/Updates
 Table 80. GlaxoSmithKline Plc Company Information
 Table 81. GlaxoSmithKline Plc Description and Business Overview
 Table 82. GlaxoSmithKline Plc Focal Segmental Glomerulosclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 83. GlaxoSmithKline Plc Focal Segmental Glomerulosclerosis Drug Product
 Table 84. GlaxoSmithKline Plc Recent Developments/Updates
 Table 85. Retrophin Inc Company Information
 Table 86. Retrophin Inc Description and Business Overview
 Table 87. Retrophin Inc Focal Segmental Glomerulosclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 88. Retrophin Inc Focal Segmental Glomerulosclerosis Drug Product
 Table 89. Retrophin Inc Recent Developments/Updates
 Table 90. Takeda Company Information
 Table 91. Takeda Description and Business Overview
 Table 92. Takeda Focal Segmental Glomerulosclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 93. Takeda Focal Segmental Glomerulosclerosis Drug Product
 Table 94. Takeda Recent Developments/Updates
 Table 95. Variant Pharmaceuticals Inc Company Information
 Table 96. Variant Pharmaceuticals Inc Description and Business Overview
 Table 97. Variant Pharmaceuticals Inc Focal Segmental Glomerulosclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 98. Variant Pharmaceuticals Inc Focal Segmental Glomerulosclerosis Drug Product
 Table 99. Variant Pharmaceuticals Inc Recent Developments/Updates
 Table 100. Key Raw Materials Lists
 Table 101. Raw Materials Key Suppliers Lists
 Table 102. Focal Segmental Glomerulosclerosis Drug Distributors List
 Table 103. Focal Segmental Glomerulosclerosis Drug Customers List
 Table 104. Focal Segmental Glomerulosclerosis Drug Market Trends
 Table 105. Focal Segmental Glomerulosclerosis Drug Market Drivers
 Table 106. Focal Segmental Glomerulosclerosis Drug Market Challenges
 Table 107. Focal Segmental Glomerulosclerosis Drug Market Restraints
 Table 108. Research Programs/Design for This Report
 Table 109. Key Data Information from Secondary Sources
 Table 110. Key Data Information from Primary Sources
 Table 111. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Focal Segmental Glomerulosclerosis Drug
 Figure 2. Global Focal Segmental Glomerulosclerosis Drug Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Focal Segmental Glomerulosclerosis Drug Market Share by Type: 2024 & 2031
 Figure 4. Losmapimod Product Picture
 Figure 5. SHP-627 Product Picture
 Figure 6. Sparsentan Product Picture
 Figure 7. TM-5484 Product Picture
 Figure 8. Others Product Picture
 Figure 9. Global Focal Segmental Glomerulosclerosis Drug Market Value by Application (2020-2031) & (US$ Million)
 Figure 10. Global Focal Segmental Glomerulosclerosis Drug Market Share by Application: 2024 & 2031
 Figure 11. Clinic
 Figure 12. Research Center
 Figure 13. Hospital
 Figure 14. Others
 Figure 15. Global Focal Segmental Glomerulosclerosis Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Focal Segmental Glomerulosclerosis Drug Market Size (2020-2031) & (US$ Million)
 Figure 17. Global Focal Segmental Glomerulosclerosis Drug Sales (2020-2031) & (K Pcs)
 Figure 18. Global Focal Segmental Glomerulosclerosis Drug Average Price (USD/Pcs) & (2020-2031)
 Figure 19. Focal Segmental Glomerulosclerosis Drug Report Years Considered
 Figure 20. Focal Segmental Glomerulosclerosis Drug Sales Share by Manufacturers in 2024
 Figure 21. Global Focal Segmental Glomerulosclerosis Drug Revenue Share by Manufacturers in 2024
 Figure 22. Global 5 and 10 Largest Focal Segmental Glomerulosclerosis Drug Players: Market Share by Revenue in Focal Segmental Glomerulosclerosis Drug in 2024
 Figure 23. Focal Segmental Glomerulosclerosis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 24. Global Focal Segmental Glomerulosclerosis Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 25. North America Focal Segmental Glomerulosclerosis Drug Sales Market Share by Country (2020-2031)
 Figure 26. North America Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Country (2020-2031)
 Figure 27. U.S. Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. Canada Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Europe Focal Segmental Glomerulosclerosis Drug Sales Market Share by Country (2020-2031)
 Figure 30. Europe Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Country (2020-2031)
 Figure 31. Germany Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. France Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. U.K. Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Italy Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Russia Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Asia Pacific Focal Segmental Glomerulosclerosis Drug Sales Market Share by Region (2020-2031)
 Figure 37. Asia Pacific Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Region (2020-2031)
 Figure 38. China Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Japan Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. South Korea Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. India Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Australia Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Taiwan Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Indonesia Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Thailand Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Malaysia Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Philippines Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Latin America Focal Segmental Glomerulosclerosis Drug Sales Market Share by Country (2020-2031)
 Figure 49. Latin America Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Country (2020-2031)
 Figure 50. Mexico Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Brazil Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Argentina Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales Market Share by Country (2020-2031)
 Figure 54. Middle East and Africa Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Country (2020-2031)
 Figure 55. Turkey Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 56. Saudi Arabia Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 57. UAE Focal Segmental Glomerulosclerosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 58. Global Sales Market Share of Focal Segmental Glomerulosclerosis Drug by Type (2020-2031)
 Figure 59. Global Revenue Market Share of Focal Segmental Glomerulosclerosis Drug by Type (2020-2031)
 Figure 60. Global Focal Segmental Glomerulosclerosis Drug Price (USD/Pcs) by Type (2020-2031)
 Figure 61. Global Sales Market Share of Focal Segmental Glomerulosclerosis Drug by Application (2020-2031)
 Figure 62. Global Revenue Market Share of Focal Segmental Glomerulosclerosis Drug by Application (2020-2031)
 Figure 63. Global Focal Segmental Glomerulosclerosis Drug Price (USD/Pcs) by Application (2020-2031)
 Figure 64. Focal Segmental Glomerulosclerosis Drug Value Chain
 Figure 65. Channels of Distribution (Direct Vs Distribution)
 Figure 66. Bottom-up and Top-down Approaches for This Report
 Figure 67. Data Triangulation
 Figure 68. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano String

SIMILAR REPORTS

Global Focal Glomerular Sclerosis FSGS Treatment Medicine Market Research Report 2025
Global Focal Nodular Glomerulosclerosis FSGS Treatment Medicine Market Research Report 2025
Focal Segmental Glomerulosclerosis FSGS Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Drugs to Treat Chronic Kidney Disease Market Research Report 2024
Global Renal Disease Treatment Market Research Report 2024
Global Renal Medical Devices Market Research Report 2024
Global Renal Biomarker Market Research Report 2025
Kidney Disease Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Proteinuria Treatment Market Insights Forecast to 2030
Global Renal Cell Cacinoma Drugs Market Research Report 2024
Global Targeted Drugs for Multiple Sclerosis Market Research Report 2024
Global Kidney Medicine Market Insights Forecast to 2030
Global Complement Drug for Kidney Disease Market Research Report 2024
Renal Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Chronic Kidney Disease Drugs Market Research Report 2025
Global Drug induced Nephrotoxicity Treatment Market Research Report 2025
Kidney Fibrosis Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Posterior Segment Eye Disease Treatment Market Research Report 2024
Immunosuppressant Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Chronic Kidney Disease Treatment Market Research Report 2025

RELATED REPORTS

Global GLP-1 Targeted Peptide Weight Loss Drugs Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19A18322
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Stimulant-Free Fat Burners Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3E3525
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Test Boosters Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-35T3049
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Salsalate Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-33Y1801
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions